BMB-101
Treatment-Resistant Depression (TRD)
Key Facts
About Bright Minds Biosciences
Bright Minds Biosciences is pioneering a new class of CNS therapeutics by designing highly selective serotonin receptor agonists. The company's mission is to address significant unmet needs in neuropsychiatry, moving beyond traditional approaches to create drugs with novel mechanisms of action. Its lead programs target 5-HT receptors implicated in mood, cognition, and seizure control, with its most advanced candidate, BMB-101, in Phase 2 development for treatment-resistant depression. The company's strategic direction involves advancing its clinical pipeline while exploring the potential of its platform in additional CNS indications.
View full company profileAbout Bright Minds Biosciences
Bright Minds Biosciences is pioneering a new class of CNS therapeutics by designing highly selective serotonin receptor agonists. The company's mission is to address significant unmet needs in neuropsychiatry, moving beyond traditional approaches to create drugs with novel mechanisms of action. Its lead programs target 5-HT receptors implicated in mood, cognition, and seizure control, with its most advanced candidate, BMB-101, in Phase 2 development for treatment-resistant depression. The company's strategic direction involves advancing its clinical pipeline while exploring the potential of its platform in additional CNS indications.
View full company profileTherapeutic Areas
Other Treatment-Resistant Depression (TRD) Drugs
| Drug | Company | Phase |
|---|---|---|
| SPN-820/821 | Supernus Pharmaceuticals | Phase 2 |
| BHV-2100 (mGluR2/3 NAM) | Biohaven | Phase 1 |
| PCN-101 (R-ketamine) | atai Life Sciences | Phase 2 |
| VLS-01 (DMT) | atai Life Sciences | Phase 1 |
| Salvianolic Acid B | atai Life Sciences | Preclinical |
| GH001 | GH Research | Phase 2b |
| MW-101 | MindWalk Holdings | Phase 2 |
| NPH-101 | Neuphoria Therapeutics | Phase 1/2 |
| CYC-126 | Cyclerion Therapeutics | Phase 2 |